Free Trial

CytomX Therapeutics (CTMX) News Today

CytomX Therapeutics logo
$2.54 +0.14 (+5.63%)
As of 10:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CTMX Latest News

CytomX Therapeutics, Inc. stock logo
Formidable Asset Management LLC Grows Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Formidable Asset Management LLC lifted its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 55.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 382,529 shares of the biotechnology c
CytomX Therapeutics, Inc. stock logo
Point72 Asset Management L.P. Invests $2.73 Million in CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Point72 Asset Management L.P. bought a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,650,000 shares of the
CytomX Therapeutics, Inc. stock logo
Tang Capital Management LLC Sells 500,000 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Tang Capital Management LLC lowered its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 6.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,311,760 shares of the bi
CytomX Therapeutics, Inc. stock logo
Equities Analysts Set Expectations for CTMX Q2 Earnings
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 earnings estimates for CytomX Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will earn $0
HC Wainwright Expects Lower Earnings for CytomX Therapeutics
CytomX Therapeutics, Inc. stock logo
Prosight Management LP Boosts Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Prosight Management LP boosted its position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 29.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,905,000 shares of the biotechnology compan
CytomX Therapeutics, Inc. stock logo
Q2 EPS Estimates for CytomX Therapeutics Cut by Wedbush
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Research analysts at Wedbush decreased their Q2 2025 earnings estimates for CytomX Therapeutics in a research report issued on Monday, May 12th. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will post earnings of (
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Given "Outperform" Rating at Wedbush
Wedbush reissued an "outperform" rating and issued a $6.00 target price (up from $5.00) on shares of CytomX Therapeutics in a report on Monday.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTMX)
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of some unusual options trading on Monday. Traders purchased 4,235 call options on the stock. This represents an increase of approximately 2,705% compared to the average volume of 151 call options.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Announces Quarterly Earnings Results
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.17. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter in the previous year, the company posted $0.17 earnings per share.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Wednesday
CytomX Therapeutics (NASDAQ:CTMX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-cytomx-therapeutics-inc-stock/)
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 288,736.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 811,630 shares of the biotechnology comp
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to
CytomX Therapeutics, Inc. stock logo
Altium Capital Management LLC Trims Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Altium Capital Management LLC decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 48.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 467,491 shares of the biotechnology compa
CytomX Therapeutics assumed with an Overweight at Piper Sandler
CytomX Therapeutics participates in a conference call with JPMorgan
CytomX Therapeutics, Inc. stock logo
StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold
StockNews.com cut CytomX Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 91.5% in March
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,000,000 shares, an increase of 91.5% from the February 28th total of 4,700,000 shares. Approximately 12.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is presently 5.0 days.
CytomX Therapeutics, Inc. stock logo
Insider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 19,512 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total transaction of $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares in the company, valued at $149,181.60. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
CytomX Therapeutics, Inc. stock logo
Sean A. Mccarthy Sells 37,656 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 37,656 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $22,593.60. Following the sale, the chief executive officer now owns 995,195 shares in the company, valued at $597,117. This represents a 3.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by StockNews.com
StockNews.com raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.
Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

CTMX Media Mentions By Week

CTMX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CTMX
News Sentiment

0.71

0.87

Average
Medical
News Sentiment

CTMX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CTMX Articles
This Week

4

2

CTMX Articles
Average Week

Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CTMX) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners